The Form 4 filing, a report of insider stock activity, was filed on November 18, 2026. It covers a trade made two days earlier, on November 16, by Sushil Patel, Replimune’s chief executive officer.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-16 |
| Date of Latest Transaction | 2026-11-16 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 49,026 |
| Price | $21.60 |
| Total Transaction Value | $1,058,961.60 |
| Insider | |
| Ticker Symbol | REPL |
| Company | Replimune Group, Inc. |
| Insider Name | Patel Sushil |
| Insider Title | Chief Executive Officer |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 659,125 |
| Position Size Change | 6.92% |
| Filing | |
| Filing Date | 2026-11-18 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a sale of 49,026 REPL shares in one transaction. It was reported with transaction code S, which identifies a sale.
What was the average price of the transaction?
The average price for the November 16, 2026, sale was $21.60 per share.
How did this transaction affect the insider's holdings?
Sushil Patel sold 49,026 shares and reported 659,125 shares owned afterward. The shares sold were 6.92% of his reported balance before the sale, or about seven out of every 100 shares.
What's the total transaction value?
The total transaction value was $1,058,961.60. That amount covers the single reported sale on November 16.
Are there any special circumstances around this transaction?
The sale is marked as tied to a tax bill or the cost of using a stock option. A stock option gives someone the right to buy shares at a set price. Code S identifies the shares as sold. No footnote text is available here to confirm the exact purpose or how any payment worked. The information does not confirm that the sale was only for taxes or that an option was exercised.
For research purposes only; not investment advice.